Member Info for Inkose

What's the ticker code for Arrowhead?

Have a look at MRK.

The FDA grants Priority Review status to AstraZeneca's (NYSE:AZN) supplemental marketing application seeking approval for Lynparza (olaparib), combined with RocheLynparza (olaparib),s Avastin (bevacizumab), for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to 1st-line platinum-based chemotherapy with bevacizumab.

TOP NEWS:
(Alliance News) - FTSE 100-listed drugsmaker AstraZeneca PLC said Friday its key cancer treatment drug Imfinzi has been granted priority review approval by US regulators after positive late-stage clinical trial data.

The US Food & Drug Administration accepted the supplemental biologics license application and granted priority review for Imfinzi - the brand name of durvalumab - for the treatment of extensive-stage small cell lung cancer.

The approval was based on the positive results of the phase three Caspian trial. The trial recently released test results in the Lancet journal which showed "statistically significant and clinically meaningful improvement" in survival rates from the drug.

Imfinzi is already approved for unresectable stage three non-small cell lung cancer in 54 countries after the phase three Pacific trial results.

Shares in Cambridge-based AstraZeneca were 0.6% lower at 7,454.00 pence in London on Friday.

By Ahren Lester; ahrenlester@alliancenews.com

I wonder how far under water you are on this company. Is it as high as 90%?

The $57 price target relates US ADRs. This qould translate to a UK price target of about £90.

AstraZeneca 'best-in-class' biopharma, SVB Leerink says

Nov. 22, 2019 12:52 PM ET|About: AstraZeneca PLC (AZN)|By: Carl Surran, SA News Editor
AstraZeneca (AZN +0.7%) enjoys modest gains after SVB Leerink initiated coverage with an Outperform rating and $57 price target, saying it expects momentum to continue even though shares have climbed significantly since 2017 and currently trade at a premium vs. peers.

Leerink's Andrew Berens thinks AZN's "focused strategy" has established the company as a best-in-class biopharma after a successful transition from a general therapeutics company to a rapidly growing oncology company with a number of multi-blockbuster drugs.

AZN also has invested in other areas of rapid growth including the emerging markets, which Berens believes will "generate additional investor value as these areas become more commercially validated and relevant."

AZN's average Sell Side Rating and Seeking Alpha Authors' Rating are both Bullish, while its Quant Rating is Neutral.

The succinct history of this company:
Jam tomorrow never today

...and then avoid buying!

One of my best decisions this year was to take the hit and sell my holding in WPCT, Painful at the time but subsequent events showed that I made the right decision.
I've been following AVCT for years and have seen the steady glide down in the SP.
What the management is really good at is telling a good story and getting new investment into the company, but this always results in existing shareholder dilution and it doesn't work. After a blip up the glide down continues.
Now I wonder, has Neil Woodford got any money left on 34 Black?

Q1. No
Q2. No
Q3. It isn't.

(Alliance News) - Construction firm Galliford Try on Wednesday reported a fall in annual profit and sliced its dividend by a quarter.

Revenue for the year to June 30 fell 7.5% to GBP2.71 billion from GBP2.93 billion, with pretax profit dipping 27% to GBP104.7 million from GBP143.7 million.

The company cut its full-year dividend 25% to 58.0p from 77.0p.

Galliford said its construction result for the year was hit by challenges in both legacy projects and some current one, though the business continues to see "good demand" in its Building and Infrastructure divisions, which are part of Galiford's Construction arm.

On Tuesday, Bovis Homes said it had resumed talks to acquire Galliford Try's housebuilding businesses.

Galliford Chief Executive Graham Prothero said on Wednesday: "The potential combination of our Linden Homes and Partnerships businesses with Bovis Homes represents a superb opportunity, enhancing the prospects for all three of our businesses to thrive as strategically focused and well-financed operations with excellent opportunities for growth. The transaction allows Construction to continue trading as a standalone well capitalised business."

The current share price is one sixth of the value in January 2016.

read 5 for %

The current SP in US$ terms is what Pfizer offered % years ago.

Who can say what the future will hold?
What follows is not advice:
If you have a known cash requirement in the next year to say to 18 months then it makes sense to cover that need.

Don't buy whilst the fund hold Industrial Heat.

Worth bearing in mind that Pfizer tried to but them tried to buy them at £55 / share. At todays exchange rate that would be equivalent to £73.50 / share

Sone knowledge of physics helps to understand that there is no theoretical basis for low energy nuclear fusion.
Note also that there has been no peer reviewed publication supporting the claim and ALL attempts at reproducing the experiment has failed.

Read Cold Fusion think alchemy.
It was realising the extent of WPCT's holding in Industrial Heating that persuaded me to swallow the loss and sell out.